PCR for HBV, HCV and HIV-1 experiences and first results from a routine screening programme in a large blood transfusion service

被引:19
作者
Schottstedt, V
Tuma, W
Bunger, G
Lefevre, H
机构
[1] Red Cross Blood Transfus Serv N Rhine Westfalia, Frankfurt, Germany
[2] GeneLAB, Gelsenkirchen, Germany
关键词
D O I
10.1006/biol.1998.0144
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
We adapted the PCR method to screen up to 3000 blood donations per day for hepatitis B, hepatitis C and HIV-1 virus contamination. Up to 600 aliquots (average 418 donations) are pooled using an automatic sample processor with disposable tips (validated to avoid contamination) taken from blood donations which are serologically negative and free for clinical usage according to federal regulations. In the case of a positive PCR pool result the viraemicdonation is identified by two additional PCR pools testing steps with smaller pool sizes. All of the steps are supported by electronic data processing. After virus concentration by ultracentrifugation, and in the case of HCV and HIV-1 an additional reverse transcription step, PCR amplifications are performed. PCRs are done for each virus in two genomic regions. Laser-induced fluorescence detection after PAGE and computer-analysis are used to identify the amplification products. Using this validated methodology routinely we have checked 428 896 donations up to the end of August 1996. During this survey we found at least 24 virus-containing donations which were negative in corresponding serological tests and would have been transfused (2 HBV-, 22 HCV-, 0 HIV-1-containing donations). It seems possible for large transfusion centres to shorten the diagnostic window periods with our PCR-methodology with acceptable costs (15 DM per donation for all three viruses including logistics, developments and investments). (C) 1998 The International Association of Biological Standardization.
引用
收藏
页码:101 / 104
页数:4
相关论文
共 7 条
[1]  
BUSCH MP, 1995, EPFA NIBSC WORKSH PO
[2]  
*P EHRL I LANG GER, 1996, BUNDESANZEIGER 0320, P3123
[3]  
SCHOTTSTEDT V, 1995, INFUSIONSTHER TRA S2, V22, P40
[4]  
SCHOTTSTEDT V, 1994, BEITR INFUSIONSTHER, V32, P28
[5]   The risk of transfusion-transmitted viral infections [J].
Schreiber, GB ;
Busch, MP ;
Kleinman, SH ;
Korelitz, JJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (26) :1685-1690
[6]  
TUMA W, 1995, INFUSIONSTHERAPIE, V22, P95
[7]  
TUMA W, 1996, 24 C INT SOC BLOOD T